Revenue growth at Hikma to slow down after strong year
13th Mar 2013 07:19
Pharmaceuticals group Hikma registered an impressive increase in revenue in 2012, helped by strong performances from both the Branded and Injectables divisions, but warned that sales growth would slow this year. After the 20.8% growth seen in 2012, the company said that the rate would reduce to ar
Read moreMonday broker round-up UPDATE
4th Mar 2013 07:12
Aggreko: JP Morgan takes target price from 1845p to 1870p, while reiterating a neutral rating. Anglo American: Nomura reduces target price from 1800p to 1700p and downgrades from neutral to reduce. ARM Holdings: Deutsche Bank increases target price from 400p to 445p, but still recommends selling.
Read moreLondon close: Strong US data prompts late rally...again
1st Mar 2013 17:13
For a third day in a row, the FTSE 100 index rallied in afternoon trade on the back of strong economic figures from America, as investors temporarily shrugged off concerns about the automatic spending cuts which kick in later today. US President Barack Obama met with congressional leaders this afte
Read moreFTSE 250 movers: Hikma soars on 'unsolicited enquiries'
1st Mar 2013 15:23
Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future, prompting a strong rise in the share price. High Street betting shop William Hill jumped after announcing th
Read moreHikma Pharma shares rise on 'unsolicited enquiries'
1st Mar 2013 11:42
Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future. In a statment the group's Chief Executive Officer said: "We have received a number of unsolicited expression
Read moreThursday broker round-up UPDATE
28th Feb 2013 07:19
AZ Electronic Materials: Goldman Sachs moves target price from 440p to 450p and retains a buy recommendation. Bovis Homes Group: Deutsche Bank shifts target price from 667p to 679p, while downgrading to hold. British American Tabacco: Investec places its target price (previously 3350p) and buy rec
Read moreThursday broker round-up UPDATE
14th Feb 2013 08:09
African Barrick Gold: Deutsche Bank cuts target price from 410p to 340p, while staying with its hold recommendation. Investec reduces target price from 405p to 315p and downgrades from buy to hold. JP Morgan lowers target price from 370p to 290p and downgrades to underweight. AG Barr: Barclays down
Read moreHikma signs agreement with EffRx for licensing of osteoporosis treatment Binesto
4th Feb 2013 10:37
FTSE 250-listed pharmaceuticals group Hikma Pharmaceuticals has signed an agreement with EffRx for the licensing and distribution of osteoporosis treatment Binosto. The treatment, which is to be distributed throughout the Middle East and North Africa (MENA), represents the only buffered solution f
Read moreTuesday broker round-up UPDATE
15th Jan 2013 07:17
African Barrick Gold: Investec lowers its target price from 526p to 405p, while upgrading from hold to buy. ARM Holdings: Morgan Stanley raises its target price from 725p to 911p, while downgrading to equal-weight. Investec ups target price from 800p to 900p and downgrades from buy to hold. Aurum
Read moreThursday tips round-up: Sainsbury's, Aviva, Hikma Pharmaceuticals
10th Jan 2013 07:10
Sainsbury's update yesterday revealed that Christmas same-store sales rose at the lowest rate seen in eight years. However, Questor thinks there was a lot to be optimistic about in the announcement. The company's like-for-like sales met expectations and its higher-margin (but cheaper) own-label good
Read moreHikma boosts Egyptian growth with acquisition
9th Jan 2013 07:59
FTSE 250 pharmaceutical group HIkma is to buy the Egyptian Company for Pharmaceuticals & Chemical Industries as it strengthens its position in a rapidly growing market. It is to pay EGP142.4m - around $22.2m - to buy the firm from a consortium of shareholders. Hikma's Chief Executive, Said Darwaz
Read moreHikma Pharmaceuticals announces launch of argatroban injection
13th Dec 2012 09:49
Hikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults. The FSTE 250 multinational group is releasing the argatroban injection after receiving approval from the US Food and Drug Administration earlier this year. The London-based pharmace
Read moreLondon close: Markets in bullish mood ahead of US election results
6th Nov 2012 16:44
- Markets gear up for climax of presidential race - Economic data disappoints - Corporate earnings impress, Resolution leads risers after upgrade The UK stock market shrugged off some disappointing economic data to finish Tuesday's session with decent gains as a barrage of updates and results from
Read moreFTSE 250 movers: Hikma rises on Panmure upgrade
6th Nov 2012 15:30
Hikma Pharmaceuticals got a boost after Panmure Gordon upgraded the stock from hold to buy and lifted its price target from 720p to 825p. Jefferies kept its buy rating on the stock and retained a 890p target. Recycled packing firm DS Smith said it continue to expect substantial year-on-year EPS gr
Read moreTuesday broker round-up
6th Nov 2012 09:03
AB Foods: Jefferies keeps hold rating and 1,365p target; Panmure Gordon ups target from 1,300p to 1,450p, hold rating kept; Investec keeps hold rating and 1,300p target. Aviva: Panmure Gordon maintains buy rating and 425p target. Babcock: Jefferies keeps buy rating and 970p target; Seymour Pierce
Read more